Disorders of gut–brain interaction in Aotearoa New Zealand: a long-standing evidence gap with unmeasured health and economic consequences
aim: The aim of this viewpoint was to summarise evidence regarding prevalence and economic burden of disorders of gut–brain interaction (DGBI), e.g., irritable bowel syndrome (IBS), in Aotearoa New Zealand and estimate their likely scale using comparable-country data. methods: We conducted a scoping review of Ovid Embase and PubMed (searched on 10 December 2025) for studies reporting adult DGBI prevalence or economic burden in New Zealand, the United Kingdom (UK) and Australia. New Zealand data were included regardless of diagnostic criteria; UK and Australian data were restricted to Rome IV studies. results: Only four New Zealand prevalence studies were identified, the most recent published in 2002; no study has reported DGBI prevalence in Māori or Pacific people. Two small, industry-linked New Zealand cost studies were identified. UK and Australian Rome IV data indicate adult DGBI prevalence of approximately 37%, with significant healthcare expenditure and productivity loss. Extrapolating UK mean direct costs per IBS patient to one-third of New Zealand’s adults, direct healthcare utilisation costs are approximately NZ$1.6 billion annually, with total costs approaching 1% of gross domestic product. conclusion: New Zealand lacks contemporary prevalence data, equity-specific data for Māori and credible cost-of-illness estimates for DGBI. Extrapolation from comparable countries suggests the true burden is large and current research and clinical investment are extraordinarily mismatched to it.
Authors
- Jody Miller
- Simone Bayer
- Nathan Berg
Publication Details
- Journal
- New Zealand Medical Journal
- Published
- 2026-11-20
- DOI
- https://doi.org/10.26635/6965.7608
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00